Greenwich LifeSciences rises after expanding late‑stage breast cancer trial

Greenwich Lifesciences

19/03/2026 10:50

** Shares of biotech firm Greenwich LifeSciences GLSI.O rise about 1.1% to $27 premarket

** Co says it has expanded its late‑stage trial of GLSI‑100, an experimental treatment aimed at preventing breast cancer recurrence

** Says trial will now include multiple City of Hope cancer centers across the U.S., including California, Arizona, Georgia and Illinois

** GLSI‑100 targets HER2‑positive breast cancer, an aggressive form of the disease that grows faster than other types

** Early data from an open‑label arm showed a 70-80% cut in cancer recurrence after standard treatment - GLSI

** Co says study run by Baylor College of Medicine and that it plans to expand trial sites to as many as 200 globally

** GLSI rose ~87% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))